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Dr. Nylander is an
Manuscript rece
accepted March 24his review constitutes a critical evaluation of recent publications that have described an additional mode of action
of the P2Y12 receptor antagonist ticagrelor. The effect is mediated by inhibition of the adenosine transporter ENT1
(type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism,
thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is
formed. Understanding the mode of action of ticagrelor is of particular interest given that its clinical proﬁle, both in
terms of efﬁcacy and adverse events, differs from that of thienopyridine P2Y12 antagonists. (J Am Coll Cardiol
2014;63:2503–9) ª 2014 by the American College of Cardiology FoundationTicagrelor is a direct-acting, reversibly binding P2Y12
antagonist that provides rapid onset of antiplatelet effects
after oral administration. P2Y12, 1 of the 2 purinergic
receptors for adenosine diphosphate (ADP) expressed by
platelets, is essential for normal ADP-induced platelet
aggregation. P2Y12 signaling ampliﬁes platelet responses
to agonists that cause ADP release from delta granules,
stabilizes platelet aggregates, and opposes the anti-
platelet effects of natural platelet inhibitors such as pro-
stacyclin that induce production of the inhibitory cyclic
adenosine monophosphate (cAMP) by activating adenylyl
cyclase (1).
The essential role of P2Y12 in hemostasis and thrombosis
is demonstrated by observations that patients with inherited
P2Y12 defects have a bleeding diathesis and that the
administration of antagonists reduces the incidence of major
adverse cardiovascular events in patients at risk (1). The
most widely used P2Y12 antagonist is the thienopyridine
prodrug clopidogrel, which, through hepatic conversion to
its active metabolite, irreversibly inhibits P2Y12. Compared
with clopidogrel, ticagrelor provides higher and much less
variable P2Y12 inhibition. This is also true for the third-
generation thienopyridine prasugrel (1), albeit ticagrelor
has been shown to provide slightly greater platelet inhibi-
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, 2014.Outcomes) study, ticagrelor was superior to clopidogrel in
preventing cardiovascular death, myocardial infarction, or
stroke (9.8% vs. 11.7%, a 16% reduction) in patients with
acute coronary syndrome (ACS); two-thirds of these pa-
tients had undergone percutaneous coronary intervention
(PCI) (3). Prasugrel was also superior to clopidogrel in
preventing the same composite endpoint in patients with
ACS who underwent PCI in the TRITON (Therapeutic
Outcomes by Optimizing Platelet Inhibition With Pra-
sugrel) trial (4). Although the 2 trials had quite different
designs, they showed that more rapid, higher, and more
consistent P2Y12 inhibition than afforded by clopidogrel
was associated with better clinical outcome. PLATO and
TRITON did display some differences. In PLATO, tica-
grelor slightly but signiﬁcantly reduced the incidence of
cardiovascular (4.0% vs. 5.1%) and total (4.5% vs. 5.9%)
mortality compared with clopidogrel, whereas no signiﬁcant
reduction in cardiovascular (2.1% vs. 2.4%) or total (3.0%
vs. 3.2%) mortality was observed with prasugrel versus
clopidogrel in TRITON (3,4). In addition, a greater inci-
dence of dyspnea and ventricular pauses was observed with
ticagrelor (3). Although the accuracy of the PLATO
mortality data has been questioned by some authors (5),
their allegations have been rebutted by the PLATO in-
vestigators (6). Thus, although alternative interpretations
exist (7), the PLATO data on mortality suggest that
ticagrelor may have unique and clinically relevant effects,
as also demonstrated by the observed increased incidence of
dyspnea and ventricular pauses (3). These effects of tica-
grelor may be accounted for by its reversible binding to
P2Y12, its systemic presence at pharmacologically active
concentrations over 24 h of the day (8), and/or by addi-
tional P2Y12-independent effects (9).
Here, we will review the experimental and clinical evi-
dence that ticagrelor increases the half-life and plasma
concentration of adenosine, and critically evaluate whether
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Adenosine is a purine nucleoside
produced primarily through the
metabolism of ADP or adenosine
triphosphate by the nucleotidases
CD39 andCD73; its plasma levels
increase after cellular stresses such
as injury, ischemia/reperfusion, or
inﬂammation (10). Adenosine is
rapidly taken up by cells throughsodium-independent equilibrative nucleoside transporters (ENT
1/2) and sodium-dependent concentrative nucleoside
transporters (CNT 2/3) (11). Intracellular adenosine is
metabolized to inosine by adenosine deaminase or
transformed into adenine nucleotides by adenosine kinase
(10,12). Because of its rapid cellular uptake and metabolism,
extracellular adenosine has a half-life of a few seconds (13),
which can be prolonged by inhibition of its transport into
cells (Fig. 1).
Several studies provide evidence that ticagrelor inhibits
cellular uptake of adenosine (11,14,15). Ticagrelor inhibited
adenosine uptake by washed human erythrocytes and by hu-
man, dog, and rat cell lines. Considering that the experiments
were performed under sodium-free conditions and with cell
lines that express ENT1 but not ENT2, it was assumed that
ticagrelor inhibits sodium-independent ENT1 (14). The
identity of the target transporter was recently conﬁrmed with
cells transfected with human transporters (ENT1, ENT2,
CNT2, and CNT3). In these experiments, ticagrelor signif-
icantly inhibited adenosine uptake only in cells that expressed
ENT1 (11). Compared with dipyridamole, an established
ENT1 inhibitor (16), ticagrelor displayed a lower afﬁnity
for the transporter (Ki 41 vs. 2.6 nmol/l). Other P2Y12 an-
tagonists, (cangrelor, elinogrel, and the active metabolites of
clopidogrel and prasugrel) did not display any signiﬁcant
activity versus any of the transporters. The main metabolites
of ticagrelor (AR-C124910XX, present in blood, and AR-
C133913XX, present in urine) showed weak ENT1 inhibi-
tion and low afﬁnity (Ki: 330 and 23,000 nmol/l, respectively).
Finally, the main metabolite of cangrelor displayed very
weak inhibition of adenosine uptake (11). The 16-fold higher
afﬁnity of dipyridamole for ENT1 relative to ticagrelor is in
line with the potency data obtained in the aforementioned
in vitro experiments (14). The afﬁnity of ticagrelor for P2Y12
(Ki 2 nmol/l or pKi 8.7) (17) is thus approximately 20-fold
higher than for ENT1. Ticagrelor 1 mmol/l, but not the
active metabolite of prasugrel, signiﬁcantly conserved adeno-
sine in human whole blood in vitro. Because the mean
maximal plasma exposure after 90 mg of ticagrelor is 1.5
mmol/l (15), these in vitro data indicate a potential for clinicalrelevance. Importantly, it has been demonstrated that tica-
grelor does not display relevant direct activity on adenosine
receptors (11,18) and is not metabolized to adenosine (19).
Biological Effects of Adenosine
Adenosine exerts its biological effects by interacting with 4
G-protein–coupled receptors: A1R and A3R are coupled to
Gi, the inhibitory G protein, which inhibits adenylyl cyclase
and thus decreases intracellular cAMP, whereas A2AR and
A2BR are coupled to the stimulatory G protein, Gs, which
stimulates adenylyl cyclase, increasing intracellular cAMP.
Of the 2 A2R subtypes, A2A is the high- and A2B the low-
afﬁnity receptor (12,20).
Effects of adenosine on blood vessels. A2AR is the main
adenosine receptor responsible for coronary vasodilation,
which is mediated by both nitric oxide-dependent and
-independent pathways (21). A2BR also mediates coronary
vasodilation, whereas both A1R and A3R negatively
modulate coronary vasodilation induced by A2AR and/or
A2BR activation (22–24). Adenosine also induces endothe-
lial progenitor cell migration via A2A and A3 (25).
Effects of adenosine on platelets. Adenosine is a potent
inhibitor of platelet aggregation in platelet-rich plasma but
not in whole blood as a consequence of its rapid uptake by
erythrocytes. This discrepancy is abolished by the addition of
dipyridamole to whole blood samples (26). Adenosine in-
hibits platelet activation mainly via A2AR but also via A2BR
(27). The gene that encodes for A2B is up-regulated after
injury and systemic inﬂammation in vivo; as a consequence,
the contribution of A2B to adenosine-mediated platelet in-
hibition appears to increase under stress conditions (28).
Effects of adenosine on inﬂammatory responses. Ade-
nosine modulates the inﬂammatory responses to a variety of
stressful conditions. Low concentrations of adenosine,
which activate A1R and A3R, promote neutrophil chemo-
taxis and phagocytosis, whereas high concentrations of
adenosine, which activate A2BR, inhibit neutrophil traf-
ﬁcking, granule release, and the production of reactive
oxygen species and inﬂammatory mediators (29). The ge-
netic deﬁciency of A2BR increased mortality in mice with
sepsis and reduced levels of inﬂammatory markers (30).
Thus, elevation of endogenous adenosine concentrations
may reduce the inﬂammatory responses. Indeed, dipyr-
idamole elevated adenosine concentrations and augmented
the anti-inﬂammatory response during experimental human
endotoxemia and was associated with a faster decline in
proinﬂammatory cytokines (31).
Effects of adenosine on the heart. Adenosine exerts car-
diac electrophysiological effects through activation of A1R.
It has a negative chronotropic effect through suppression of
the automaticity of cardiac pacemakers and a negative dro-
motropic effect through inhibition of AV nodal conduction
(32). These effects of adenosine constitute the rationale for
its use as a diagnostic and therapeutic agent (e.g., treatment
of supraventricular tachycardia) (33).
Figure 1
Formation of Adenosine and its Intracellular Uptake and Metabolism, Which Are Reduced by Ticagrelor Through
Inhibition of ENT1
Adenosine is formed locally at sites of hypoxia and tissue damage through degradation of released adenosine triphosphate (ATP) and adenosine diphosphate (ADP) by CD39 and
CD73 and is rapidly internalized by cells through equilibrative nucleoside transporter 1 (ENT1). Because adenosine degradation is primarily restricted to the intracellular space,
inhibition of cellular uptake of adenosine via ENT1 effectively prolongs the half-life of adenosine, thereby increasing its extracellular concentration. As a consequence, ENT1
inhibition by ticagrelor results in enhanced responses to adenosine, mediated by interaction with the adenosine receptor subtypes A1R, A2AR, A2BR, and A3R, which are coupled
to Gs or Gi proteins. AMP ¼ adenosine monophosphate; cAMP ¼ cyclic adenosine monophosphate.
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Timely coronary reperfusion improves outcomes in patients
with ACS, although reperfusion itself may contribute to
the extent of irreversible myocardial injury (reperfusion
injury). Adenosine reduced ischemia/reperfusion injury in
humans (34,35) and in animal models (10). A recent meta-
analysis of 7 randomized clinical trials indicated that in-
tracoronary adenosine administration increased post-PCI
ST-segment resolution and reduced residual ST-segment
elevation and the incidence of major adverse cardiovascular
events, although the latter did not reach statistical signiﬁ-
cance (36). Additionally, infarct size in post-PCI patients
was reduced by high-dose intracoronary adenosine (37)
or continuous intravenous adenosine infusion (38); howev-
er, another study failed to show any beneﬁcial effect of
adenosine in patients undergoing PCI, likely because of
the very low risk of the enrolled patients (39). As an
alternative to infusion of exogenous adenosine, inhibition of
ENT1 might exert cardioprotective effects by increasing the
concentration of endogenous adenosine. Indeed, ENT1
knockout mice had a reduced infarct size after ischemia/
reperfusion (40), and dipyridamole reduced infarct size
in rabbits (41) and improved heart function after PCI in
patients (42).Effects of adenosine on sensory nerves. Adenosine
stimulates pulmonary vagal C ﬁbers through A1R and
A2AR, which mediates the sensation of dyspnea (43).
Effects of adenosine on the kidney. Coordination be-
tween kidney blood ﬂow and glomerular ﬁltration rate with
tubular reabsorption is maintained by the tubuloglomerular
feedback system and metabolic products; adenosine
triphosphate and adenosine (through A1R) mediate tubu-
loglomerular feedback via afferent arteriolar vasoconstric-
tion. Tubuloglomerular feedback responsiveness was
signiﬁcantly attenuated in the absence of ENT1 in mice
(44), and dipyridamole decreased diuresis in patients, in
part in relation to a fall in glomerular ﬁltration rate (45).Ticagrelor Increases the Biological Effects of
Exogenous Adenosine
Ticagrelor increases the effects of exogenous adenosine
on blood vessels. Ticagrelor, like dipyridamole, dose-
dependently increased local blood ﬂow in the coronary ar-
tery of dogs after infusion of adenosine (14). Similar results
were obtained in healthy volunteers, who had 180 mg of
ticagrelor signiﬁcantly enhance the coronary blood ﬂow
velocity increases induced by adenosine infusion (46). There
Figure 2 Selection of Effects Mediated by Ticagrelor and Adenosine
There are similarities between the biological effects of adenosine (right) and the pharmacological effects of ticagrelor (left), which suggests that at least some of the latter
may be mediated by the drug-induced inhibition of equilibrative nucleoside transporter type 1, which causes an increase in plasma concentration of adenosine. ACS ¼ acute
coronary syndrome(s); CV ¼ cardiovascular; MACE ¼ major adverse cardiovascular effect(s).
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velocity and the plasma concentration of ticagrelor but not
for its metabolite AR-C124910XX, which has low afﬁnity
for ENT1 (11). These data were conﬁrmed in patients
with non–ST-elevation myocardial infarction undergoing
PCI: ticagrelor (90 mg bid), but not prasugrel (10 mg o.d.),
signiﬁcantly enhanced the increases in coronary blood ﬂow
velocity induced by adenosine infusion (47).
Ticagrelor increases the inhibitory effect of exogenous
adenosine on platelet aggregation. In vitro, ticagrelor
unmasked the inhibitory effect of exogenous adenosine on
platelet aggregation in whole blood from healthy volunteers
and patients with inherited severe P2Y12 deﬁciency (15).
The effect of ticagrelor on platelet aggregation was greater
than that of dipyridamole, despite the fact that dipyridamole
inhibited adenosine clearance more efﬁciently than tica-
grelor. This may be explained by the fact that ticagrelor, by
opposing the P2Y12-mediated inhibition of adenylyl cyclase,
enhanced the antiplatelet effect of adenosine, which, by
interacting with A2AR, activates adenylyl cyclase and in-
creases cAMP (1,15).
Ticagrelor increases the sensation of dyspnea caused by
exogenous adenosine. Ticagrelor (180 mg) signiﬁcantly
enhanced the sensation of dyspnea, measured by the Borg
scale, after adenosine infusion in healthy volunteers (46).The increase in sensation of dyspnea was attenuated by
intravenous administration of theophylline.
Effects of Ticagrelor on Plasma Levels of
Endogenous Adenosine and on its
Biological Effects
Studies in animal models suggest that ticagrelor en-
hances the biological effects of endogenous adenosine. A
study of coronary blood ﬂow after local ischemia by
temporary coronary artery occlusion in dogs showed that
ticagrelor, like dipyridamole, dose-dependently increased
local blood ﬂow, likely mediated by endogenous adeno-
sine (14).
In a canine model of electrolytic injury–induced thrombus
formation, ticagrelor, initiated 5 min before reperfusion by
tissue plasminogen activator, reduced infarct size by
approximately 60%. Clopidogrel had no protective effect
under the same experimental conditions. Because both
P2Y12 antagonists were dosed to completely inhibit P2Y12
but only ticagrelor reduced infarct size, these data indicate
a P2Y12-independent cardioprotective effect of ticagrelor
(48). A subsequent reperfusion study in rats conﬁrmed that
ticagrelor reduced infarct size, whereas clopidogrel had no
effect, and provided evidence that the effect of ticagrelor










Ticagrelor Yes (reversible) Yes (þ) Yes (þþ)
Cangrelor Yes (reversible) No* Yes (þþ)
Elinogrel Yes (reversible) No Yes (þþ)
Clopidogrel Yes (irreversible) No Yes (þ/)y
Dipyridamolez No Yes (þþ) No
*The main metabolite of cangrelor showed weak inhibition of adenosine uptake but no afﬁnity
versus the equilibrative nucleoside transporter type 1 (11). yClopidogrel increased the incidence of
dyspnea in clinical trials, albeit to a lesser degree than the reversible P2Y12 antagonists. In the
PLATO (Platelet Inhibition and Patient Outcomes) (58) and ONSET/OFFSET (A Study of the Onset
and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin) (59)
studies, dyspnea was considered unexplained or likely or possibly caused by the study drug in
20.1% (160 of 798) and 40% (2 of 5) of clopidogrel-treated patients, respectively. Moreover,
13 patients in the PLATO study (58) discontinued clopidogrel treatment because of the severity
of dyspnea. Finally, in a study by Serebruany et al. (60), 4.2% (157 of 3,719) of patients
who underwent percutaneous coronary intervention developed dyspnea, which was attributable to
underlying diseases in most instances but remained unexplained in 10.8% (17 of 157).
zDipyridamole induces dyspnea after intravenous infusion at high doses, as in dipyridamole-
thallium imaging for the evaluation of coronary artery disease, but not when given orally at
therapeutic doses.
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completely reversed by an adenosine receptor antagonist
(49). Although the results of these studies suggest that under
the experimental conditions that were tested, the car-
dioprotective effect of ticagrelor is mediated by the induced
increase in adenosine and not by its inhibitory effect on
P2Y12, previous studies demonstrated that other antiplatelet
agents that do not affect ENT1 were cardioprotective
(50,51).
In light of these data, the important question to address
is whether or not ticagrelor, when administered to humans
at clinically approved doses, increases the levels of adenosine
and enhances the biological effects of adenosine. Indeed,
a recent study in patients with ACS revealed that adenosine
plasma concentrations were signiﬁcantly higher in blood
samples taken 6 h after ticagrelor (180 mg) compared
with clopidogrel (600 mg) (18). Moreover, serum from
ticagrelor-treated patients, but not from clopidogrel-
treated patients, inhibited in vitro uptake of exogenous
adenosine by erythrocytes (18). These results conﬁrm that
the concentration of ticagrelor attained in vivo after oral
administration is sufﬁcient to inhibit cellular uptake of
adenosine, thereby prolonging its half-life and increasing
its concentration.
The effect of ticagrelor on in vivo adenosine concentra-
tions may convey unique properties of the drug not shared by
other P2Y12 antagonists. Although it is a matter of
conjecture, a number of reported clinical effects of ticagrelor,
including its increased serum creatinine levels, improved
endothelial function (52), and protection from the conse-
quences of pulmonary infection (53), are compatible with an
enhanced effect of adenosine (Fig. 2).
However, on the basis of 2 considerations, the increase in
endogenous adenosine is unlikely to be the main cause of
the increased incidence of the sensation of dyspnea inticagrelor-treated patients, although it might contribute
partially. First, dipyridamole, a stronger ENT1 inhibitor
than ticagrelor, has not been reported to increase the
sensation of dyspnea when administered orally at doses able
to enhance the effect of exogenous adenosine (54). Second,
P2Y12 antagonists that do not signiﬁcantly inhibit ENT1
increase the sensation of dyspnea (8,11). This is particularly
evident for cangrelor and elinogrel, which, like ticagrelor
but unlike thienopyridines, reversibly bind P2Y12 (Table 1),
and mechanisms responsible have been hypothesized (8,55).
Furthermore, it is unlikely that the ticagrelor-mediated in-
crease in adenosine accounts for the observed increased
incidence in ventricular pauses, because these were of
sinoatrial origin (56), whereas adenosine primarily affects
atrioventricular conductivity (32), although it may also
modulate the hyperpolarization-activated current (If), as
shown in rabbit sinoatrial myocytes (57).
Conclusions
Several studies consistently showed that ticagrelor inhibits
the cellular uptake of adenosine, in addition to antagonizing
the P2Y12 receptor. This effect of ticagrelor is sufﬁcient to
increase the circulating levels of adenosine in patients. To
what extent the adenosine-mediated mode of action con-
tributes to the clinical proﬁle of ticagrelor is not yet docu-
mented. Further studies are required to better elucidate the
extent to which enhanced adenosine responses contribute to
the clinical proﬁle of ticagrelor.
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